Summit Therapeutics (SMMT) Change in Acquisitions & Divestments (2023 - 2026)

Summit Therapeutics has reported Change in Acquisitions & Divestments for 4 years, with the latest figure at $177.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Acquisitions & Divestments rose 10.44% year-over-year to $177.3 million; the trailing twelve-month figure through Mar 2026 stood at $328.1 million (down 38.96% YoY), and the FY2025 full-year result was $311.3 million, down 36.44% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $177.3 million, up from $150.8 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $233.0 million in Q4 2024, with the low at $38.2 million in Q2 2023.
• Historically, Change in Acquisitions & Divestments has averaged $118.7 million across 4 years, with a median of $111.1 million in 2023.
• The largest YoY upside for Change in Acquisitions & Divestments was 284.66% in 2024 against a maximum downside of 32.37% in 2024.
• Summit Therapeutics' Change in Acquisitions & Divestments stood at $60.6 million in 2023, then surged by 284.66% to $233.0 million in 2024, then plunged by 35.27% to $150.8 million in 2025, then grew by 17.56% to $177.3 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $177.3 million (Q1 2026), $150.8 million (Q2 2025), and $160.5 million (Q1 2025), per Business Quant data.